Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Matthew S. Davids et al.|The Lancet|2021Cited by 456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J. Gordon, Alexey V. Danilov, Michael C. Churnetski et al.|Cancer|2018Cited by 86
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Lei Feng et al.|Journal of Hematology & Oncology|2023Cited by 52
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Imran Nizamuddin et al.|Blood Advances|2022Cited by 50